Monday, April 27, 2009


As global fears of swine flu rise, there has been one surprising beneficiary -- investors in Foster City-based Gilead Sciences Inc. and U.K. drugmaker GlaxoSmithKline. Shares of both companies are trading up because they are behind flu treatments that are currently being used to combat the disease -- Gilead (NASDAQ: GILD) is the co-developer of Tamiflu, and GlaxoSmithKline (NYSE: GSK) controls Relenza. The U.S. government released a quarter of its stockpiles of the drugs after declaring a national health emergency with at least 20 cases of swine flu confirmed.

I'm not saying the pharmaceutical industry is behind this whole swine flu thing, I'm just wondering if they are the most trustworthy group of folk.

No comments:

Blog Archive